Hodgkin's and Castleman's disease in a patient with systemic mastocytosis.

Abstract

Systemic mastocytosis is a rare condition characterized clinically by the local consequences of vasoactive peptides released from infiltrating mast cells in the reticuloendothelial tissues. Mast cells originate from the pluripotent bone marrow stem cells; it is therefore not surprising that myeloproliferative and myelodysplastic disorders commonly coexist or terminate the clinical phase of mastocytosis. We report here, to our knowledge, the first case of Hodgkin's and Castleman's disease occurring in a patient with co-existent systemic mastocytosis, which remained unchanged after combination chemotherapy for Hodgkin's disease.

• Authors: P Saletti, M Ghielmini, G Scali, E Pedrinis, M Guéneau, F Cavalli
• Journal: Annals of hematology (Ann Hematol) Vol. 78 Issue 2 Pg. 97-100 (Feb 1999) ISSN: 0939-5555 [Print] Germany
• PMID: 10089028 (Publication Type: Case Reports, Journal Article)

Chemical References

• Bleomycin
• Vincristine
• Methotrexate

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bleomycin (administration & dosage)
• Bone Marrow (pathology)
• Castleman Disease (complications, pathology)
• Combined Modality Therapy
• Hodgkin Disease (complications, drug therapy, pathology, radiotherapy)
• Humans
• Lymph Nodes (pathology)
• Male
• Methotrexate (administration & dosage)
• Middle Aged
• Neoplastic Stem Cells (pathology)
• Urticaria Pigmentosa (complications, pathology)
• Vincristine (administration & dosage)